It is out of our scope to review the treatment of HSP-IgAN [28] but obviously the treatment should target the risk factors when present: adequate control of hypertension with blood pressure below 130/80; reduction of proteinuria with ACE inhibitors and ARB’s; steroid treatment for severe renal lesions eventually associated to immunosuppressive agents. Here, ACE is linked to hereditary spastic paraplegia.